08:00 , Feb 2, 2012 |  BC Innovations  |  Targets & Mechanisms

Closing the gap on liver toxicity

U.S. researchers have identified a small molecule gap junction inhibitor that protects mice from drug-induced liver toxicity. 1 The team has founded Heprotech Inc. to further characterize and optimize the inhibitor. Gap junctions are multiprotein...
08:00 , Dec 16, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Psoriasis TRAF3 interacting protein 2 (TRAF3IP2; ACT1); inducible nitric oxide synthase 2 (NOS2; iNOS); F-box and leucine-rich repeat protein 19...
08:00 , Nov 3, 2003 |  BC Week In Review  |  Company News

Nanogen, Institute Pasteur deal

Institute Pasteur granted NGEN exclusive European rights to IP covering the detection of mutations in the GJB2 gene to diagnose hereditary deafness. Nanogen plans to develop a molecular diagnostic product to screen newborns for hereditary...